Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its lead product candidate is taletrectinib, an ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer; Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; NUV-868, a binding domain 2 selective, oral, small molecule bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Inc. Class A

RBC Capital analyst Leonid Timashev maintained a Buy rating on Nuvation Bio on April 6 and set a price target of $20.00. The company’s shares close...

RBC Capital Sticks to Their Buy Rating for Nuvation Bio (NUVB)

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Nuvation Bio, with a price target of $12.00. Roy covers the Hea...

JonesTrading Sticks to Their Buy Rating for Nuvation Bio (NUVB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvation Bio (NUVB) and Eli Lilly & Co (LLY) with bu...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Wedbush analyst David Nierengarten maintained a Buy rating on Nuvation Bio today and set a price target of $11.00. Nierengarten covers the Healthca...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NUVB	$4.63	+2.21%	1.97M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NUVB	$4.63	+2.2%	1.97M
3
4
5
6

NUVB

NUVB

No Data Available

Get Nuvation Bio Inc. Class A Data in Excel

Get Nuvation Bio Inc. Class A Data in Excel